Table 2.
Reference | Country | n | Cutoff values | Criteria | Validated in | |
Takada et al[61],2007 | Japan | 125 | DCP: 400 | Kyoto criteria: up to 10 tumors ≤ 5 cm and DCP ≤ 400 | Fujiki et al[63], 2009; Kaido et al[64], 2013 | |
Soejima et al[62], 2007 | Japan | 60 | DCP: 300 | Kyushu criteria: any number of tumors < 5 cm and DCP < 300 | Shirabe et al[65], 2011 | |
Todo et al[66], 2007 | Japan | 551 | AFP:200, DCP: 100 | A-P level: AFP ≤ 200 and DCP ≤ 100 | ||
Chaiteerakij et al[70], 2015 | United States | 127 | AFP:250, DCP: 7.5 | |||
Yang et al[67], 2016 | Korea | 88 (training cohort); 198 (validation cohort) | AFP: 200; DCP: 200 | A-P 200: AFP ≤ 200 or DCP ≤ 200 | ||
Kim et al[68], 2016 | Korea | 461 | AFP: 150; DCP:100 | -- | ||
Lee et al[69], 2016 | Korea | 566 | AFP and DCP; continuous variables | MoRAL score: 11x√ DCP + 2x√AFP |
AFP: Alpha-fetoprotein; DCP: Des-gamma-carboxyprothrombin; MoRAL: Model of recurrence after liver transplantation.